StockNews.AI
CYTK
StockNews.AI
40 days

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

1. Cytokinetics to present aficamten results at European Society of Cardiology Congress. 2. MAPLE-HCM trial shows positive results in obstructive hypertrophic cardiomyopathy. 3. Discussions on atrial fibrillation incidence across aficamten trials scheduled. 4. Aficamten may gain regulatory approval following favorable trial outcomes. 5. Cytokinetics advances cardiac therapies with multiple ongoing clinical trials.

8m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results and significant presentations increase investor confidence in CYTK's pipeline and potential revenues. Similar cases like Regeneron Pharmaceuticals saw stock increases with successful trial announcements.

How important is it?

The article highlights key presentations on aficamten's efficacy, potentially positioning CYTK favorably in the market.

Why Long Term?

Regulatory approval and market entry of aficamten could take time but promise sustained growth. Historical examples show delayed responses after approvals lead to price upside.

Related Companies

REGNAMGNALNY
Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM). Oral Presentations Title: MAPLE-HCM: Aficamten vs Metoprolol in Obstructive HCMPresenter: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor, Centro Nacional de Investigaciones Cardiovasculares both in Madrid, SpainDate: August 30, 2025Session Title: Hot Line 2Session Time: 8:15 - 9:45 AM CESTPresentation Time: 9:18 AM CESTLocation: Madrid (Main Auditorium) Title: REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with AficamtenPresenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science UniversityDate: August 31, 2025Session Title: Late-Breaking Clinical Science: CardiomyopathiesSession Time: 4:15-5:15 PM CESTPresentation Time: 4:45 PM CESTLocation: Budapest (Hall 10) Title: Efficacy and Safety of Long-Term Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST-HCMPresenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular CenterDate: August 31, 2025Session Title: Hypertrophic Cardiomyopathy: From Gene to TreatmentSession Time: 5:00 - 6:00 PM CESTPresentation Time: 5:40 PM CESTLocation: Science Box 4 (Research Gateway) Poster Presentations Title: Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Pre-Specified Analysis of MAPLE-HCM Presenter: Sheila Hegde, M.D., M.P.H, Assistant Professor, UT Southwestern Medical Center, Dallas, TX, Affiliate Faculty, Brigham and Women's Hospital, Boston, MAFinal presentation date and time to be confirmed Title: Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science UniversityFinal presentation date and time to be confirmed About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact:Cytokinetics Diane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Related News